Dr. Bekaii-Saab completed his undergraduate studies at McGill University in Montreal, Canada followed by medical school at the American University of Beirut in Lebanon. He completed his residency in internal medicine at the Indiana University Medical Center in Indianapolis followed by fellowships in hematology/oncology and clinical pharmacology at Tufts University-New England Medical Center in Boston.
Dr. Bekaii-Saab joined the faculty at The Ohio State University – The Arthur G. James Cancer Hospital in 2002 where he is now an Associate Professor of Medicine and Pharmacology as well the Medical Director for the Gastrointestinal Cancer program.
He is the leader of the Gastrointestinal Cancer Disease Specific Committee, which helps to oversee and organize the research operation for the above cancers at the OSU Comprehensive Cancer Center.
Dr. Bekaii-Saab’s research is focused on drug development and experimental therapeutics as pertaining to gastrointestinal malignancies and more specifically pancreatico-biliary cancers. He holds a joint appointment in the departments of Medicine (Division of Medical Oncology) and Pharmacology, which supports his focus in developing his clinical research studies.
Dr. Bekaii-Saab is the principal investigator on numerous clinical trials, including studies supported through research grants from the National Cancer Institute (NCI) and the National Comprehensive Cancer Network (NCCN). He is the recipient of numerous research grants from various industry partners. Dr. Bekaii-Saab has authored multiple publications in a number of high impact journals including Journal of Clinical Oncology, Annals of Oncology and Clinical Cancer Research amongst others. He has presented his research at numerous international forums including ASCO, AACR, ASCO GI, ESMO and ESMO GI.